First eviQ broad indication tumour-agnostic immunotherapy protocol published
This generic protocol has been developed specifically to support health professionals in prescribing and administering ipilimumab and/or nivolumab in accordance with the PBS reimbursed tumour-agnostic indication. It differs from the standard eviQ protocol template.
ID 4660: Tumour-agnostic advanced or metastatic ipilimumab and/or nivolumab
Read more about this new protocol in their FAQs.